FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

FDA has approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc. The approval indicates the supplemental submission has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion
• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

SUPPL AP for EYLEA (AFLIBERCEPT)